IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout
- Sponsor
- Helga Ellingsgaard
- Study ID
- NCT05349149
- Status
- Completed
Conditions
- Glycogen Depletion
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - 40 Years
- Healthy Volunteers
- Accepted
Interventions
- Tocilizumab/Actemra® (Roche) — DRUGThe infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
- Saline 9% — DRUGThe infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
Study Details
The aim of the study is to investigate the role of exercise-induced IL-6 in regulating energy stores and energy metabolism during recovery after an acute exercise bout. To achieve this, 30 men will be randomized to infusion placebo or tocilizumab (IL-6 receptor antibody) combined with a 2-hour exercise bout. Stable isotope tracers will be infused to determine substrate kinetics. Indirect calorimetry will be applied to determine substrate oxidation, and muscle biopsies will be taken to determine substrate uptake and storage.
Key Dates
- Start date
- Apr 20, 2022
- Status verified
- Oct 2022
- Primary completion
- Oct 11, 2022
- Completion
- Oct 11, 2022
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: TocilizumabParticipants will receive one 30 min intravenous infusion of tocilizumab/Actemra® (Roche). The dose will be 8 mg/kg bodyweight or a maximum of 800mg. Tocilizumab is dissolved in 100 mL 0.9% saline.
- Placebo Comparator: SalineAs placebo, participants will receive one 30 min intravenous infusion of 100 mL 0.9% saline.
Primary Outcome Measure
Change in muscle glycogen content (mmol/kg/h) [ Time Frame: Measured at 0, 120, 180 and 360 minutes ]